Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oleg Gluz

Showing results (41-50 of 97) with videos related to

Pageof 10
Sort By:
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 17, 2017
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2βMieke Raap, Malte Gronewold, Henriette Christgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Breast Cancer Research and Treatment|February 28, 2015
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trialRamona Erber, Oleg Gluz, Nils Brünner, et al.
Breast (Edinburgh, Scotland)|June 24, 2021
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrialsMonika Graeser, Nadia Harbeck, Oleg Gluz, et al.
Breast Cancer Research : BCR|September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialCornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
Cancer|August 12, 2020
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancerMatthias Christgen, Oleg Gluz, Nadia Harbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast CancerUlrike Nitz, Oleg Gluz, Michael Clemens, et al.
Breast Care (Basel, Switzerland)|March 15, 2021
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer PatientsRachel Wuerstlein, Nadia Harbeck, Eva-Maria Grischke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancerNicolaus Kröger, Markus Frick, Oleg Gluz, et al.
International Journal of Cancer|June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trialOleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
Pageof 10

Showing results (41-50 of 97) with videos related to

Sort By:
Pageof 10
Laboratory Investigation; a Journal of Technical Methods and Pathology|October 17, 2017
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2βMieke Raap, Malte Gronewold, Henriette Christgen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2026
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerOleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Breast Cancer Research and Treatment|February 28, 2015
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trialRamona Erber, Oleg Gluz, Nils Brünner, et al.
Breast (Edinburgh, Scotland)|June 24, 2021
The use of breast ultrasound for prediction of pathologic complete response in different subtypes of early breast cancer within the WSG-ADAPT subtrialsMonika Graeser, Nadia Harbeck, Oleg Gluz, et al.
Breast Cancer Research : BCR|September 2, 2022
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trialCornelia Kolberg-Liedtke, Friedrich Feuerhake, Madlen Garke, et al.
Cancer|August 12, 2020
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancerMatthias Christgen, Oleg Gluz, Nadia Harbeck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2019
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast CancerUlrike Nitz, Oleg Gluz, Michael Clemens, et al.
Breast Care (Basel, Switzerland)|March 15, 2021
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer PatientsRachel Wuerstlein, Nadia Harbeck, Eva-Maria Grischke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 22, 2006
Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancerNicolaus Kröger, Markus Frick, Oleg Gluz, et al.
International Journal of Cancer|June 5, 2019
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trialOleg Gluz, Cornelia Kolberg-Liedtke, Aleix Prat, et al.
Pageof 10